MEDICAL DISCLAIMER: Educational research guidelines only. Lyophilized peptides are investigational chemical compounds and are NOT approved for human consumption, diagnosis, or therapy. Consult a licensed physician before any research application.
Chonluten Dosage Chart, Schedule & Reconstitution Protocol
Quickstart Highlights
Chonluten (Thr-Glu-Asp-Gly, T-EDG) is a short tetrapeptide developed by Vladimir Khavinson and the St Petersburg Institute of Bioregulation and Gerontology as part of the cytomedine/cytogen program that produced Epitalon, Vesugen, and others. Khavinson peptides are hypothesized to bind specific gene promoter regions and modulate tissue-specific transcription; Chonluten is targeted toward bronchial epithelium and lung tissue, where it is claimed to normalize cell proliferation, support mucosal repair, and modulate cytokine signaling in chronic obstructive pulmonary disease, bronchitis, and atherosclerosis-related vascular endothelium [PMID: 24505781]. The peptide is sold as an oral capsule (Chonluten or Khavinson Peptides line) and is approved in Russia as a dietary bioregulator, not as a drug. Outside the Russian Khavinson-affiliated literature, there is essentially no independent randomized clinical evidence, and pharmacokinetics and oral bioavailability have not been characterized in peer-reviewed Western journals.
Reconstitute: Add 3 mL bacteriostatic water → 6.67 mg/mL concentration.
Easy measuring: At 6.67 mg/mL, 1 unit = 0.01 mL = 0.0667 mg (67 mcg) on a U-100 insulin syringe.
Storage: Lyophilized refrigerated or frozen; reconstituted refrigerated; avoid repeated freeze–thaw.
Russian bioregulator status only: Chonluten is registered in Russia as a dietary supplement/bioregulator, not as a pharmaceutical. It has no FDA, EMA, or MHRA approval and is not part of any Western standard of care.
Evidence base is single-group: Almost all clinical and preclinical publications come from Khavinson, Anisimov, and affiliated St Petersburg researchers; independent replication is sparse and meta-analytic evidence is essentially absent.
Oral peptide bioavailability question: Khavinson tetrapeptides are claimed to survive gastric digestion intact and signal through gene-promoter binding, but this mechanism is debated outside the Russian literature and has not been validated by Western pharmacology groups.
Quick Protocol Navigation
Reconstitution Instruction & Mixing Step-by-Step
Lyophilized powder must be reconstituted carefully. Agitating peptide chains can shear disulfide bonds and render the peptide biologically inert.
Draw 3.0 mL bacteriostatic water with a sterile syringe.
Inject slowly down the vial wall; avoid foaming.
Gently swirl/roll until dissolved (do not shake).
Inject slowly; wait a few seconds before withdrawing the needle.
Do not aspirate for subcutaneous injections; inject slowly and steadily[4].
Interactive Chonluten Syringe Calculator
Currently visualizing the 20 mg vial reconstituted with 3 mL bacteriostatic water. Adjust the target dose to dynamically render syringe units.
Reconstitution Calculation: 20mg dry powder in 3mL water yields 6.67 mg/mL. To evaluate a 250mcg dose, pull to 3.8 units (4 syringe ticks).
U-100 Syringe Representation
3.8 Units (4 Ticks)
Educational reference visual. Assumes standard U-100 insulin syringe where 1.0 mL volume = 100 units.
Titration & Dose Escalation Schedules
| Week | Daily Dose (mcg) | Units (per injection) (mL) |
|---|---|---|
| Weeks 1–2 | 250 mcg (0.25 mg) | 3.75 units (0.0375 mL) |
| Weeks 3–4 | 500 mcg (0.5 mg) | 7.5 units (0.075 mL) |
| Weeks 5–6 | 1,000 mcg (1 mg) | 15 units (0.15 mL) |
| Weeks 7–8 | 1,500 mcg (1.5 mg) | 22.5 units (0.225 mL) |
| Weeks 9–10 | 2,000 mcg (2 mg) | 30 units (0.30 mL) |
| Weeks 11–12 | 3,000 mcg (3 mg) | 45 units (0.45 mL) |
| Weeks 13–14 | 4,000 mcg (4 mg) | 60 units (0.60 mL) |
| Weeks 15–16 | 4,000 mcg (4 mg) | 60 units (0.60 mL) |
Administration guidelines: Refer to guidelines | 3 mL Reconstitution
Research Supplies Quantity Planner
Scientific mathematical planning of syringes, bacteriostatic water and dry vials needed for extended research blocks using the 20 mg vial.
Peptide Vials (Chonluten, 20 mg each):
- check8 weeks ≈ 3 vials (45.5 mg total)
- check12 weeks ≈ 6 vials (115.5 mg total)
- check16 weeks ≈ 12 vials (227.5 mg total)
Insulin Syringes (U‑100):
- checkPer week: 7 syringes (1/day)
- check8 weeks: 56 syringes
- check12 weeks: 84 syringes
- check16 weeks: 112 syringes
Bacteriostatic Water (10 mL bottles): Use 3.0 mL per vial for reconstitution.
- check8 weeks (3 vials): 9 mL → 1 × 10 mL bottle
- check12 weeks (6 vials): 18 mL → 2 × 10 mL bottles
- check16 weeks (12 vials): 36 mL → 4 × 10 mL bottles
Alcohol Swabs: One for the vial stopper + one for the injection site each day.
- checkPer week: 14 swabs (2/day)
- check8 weeks: 112 swabs → recommend 2 × 100‑count boxes
- check12 weeks: 168 swabs → recommend 2 × 100‑count boxes
- check16 weeks: 224 swabs → recommend 3 × 100‑count boxes
Mechanism of Action (MOA)
Chonluten is a synthetic tripeptide composed of glutamic acid, aspartic acid, and glycine (Glu-Asp-Gly, EDG) and is part of the broader Khavinson family of short peptide bioregulators developed at the St. Petersburg Institute of Bioregulation and Gerontology over the past four decades. Vladimir Khavinson and colleagues isolated and synthesized a series of short peptides (typically two to four amino acids) targeted at specific tissues based on extracts of those same tissues from young animals. Each Khavinson peptide is designated for a specific organ system: thymalin and thymogen for thymus, epithalon (epithalamin) for pineal, livagen for liver, prostamax for prostate, cortagen for cortex, and Chonluten (T-34) for the bronchopulmonary system [1]. The proposed mechanism of action of Khavinson peptides is described as 'epigenetic regulation through direct interaction with DNA' or 'tissue-specific gene regulation.' In published Russian and English-language reviews from the Khavinson group, short peptides are reported to penetrate cell and nuclear membranes (due to their small size of ~300–500 Da), bind to double-stranded DNA at specific promoter regions, and modulate transcription of tissue-specific genes. For Chonluten, target genes are reported to include stress-response genes (c-Fos, heat shock protein 70), antioxidant enzymes (superoxide dismutase, catalase), inflammatory mediators (cyclooxygenase-2, tumor necrosis factor-alpha), and differentiation/proliferation markers in bronchial epithelium [2]. The broader pharmacological narrative around Chonluten emphasizes restoration of bronchial epithelial function in age-related and inflammatory respiratory disease. Reported preclinical effects include increased ciliated cell density and goblet cell organization in aged rodent bronchi, improved mucociliary clearance, reduced inflammatory infiltration in models of chronic obstructive pulmonary disease (COPD), and normalization of antioxidant enzyme activity in lung tissue exposed to oxidative stress. Khavinson and colleagues have published gerontological studies arguing that long-term cyclic administration of tissue-specific peptide bioregulators extends lifespan and reduces age-associated morbidity in rodents, although the methodology and external replication of these findings have been the subject of scientific debate [1]. Clinically, Chonluten is used in Russian, Eastern European, and increasingly online retail contexts for chronic respiratory conditions including COPD, asthma, bronchitis, and post-pneumonia recovery. Some practitioners include it in broader longevity protocols combined with other Khavinson peptides such as Bronchogen (AEDL), Vesugen (KED for vasculature), and Pinealon (EDR for nervous system). Standard subcutaneous research dosing is approximately 100–200 mcg per day for 10–20 day cycles, with cycles repeated every three to six months. Oral and intranasal formulations are also reported, though parenteral routes are most common in published studies. Evidence outside the Khavinson group's own publications is sparse, and Chonluten has not been studied in randomized controlled trials by independent groups, evaluated by the FDA or EMA, or included in any internationally accepted clinical practice guideline for respiratory disease. Mechanistic claims about direct DNA binding by Khavinson peptides have been criticized in the broader peptide and structural biology literature as lacking rigorous biophysical support, although gene-expression changes in tissue and cell culture exposed to Khavinson peptides have been documented [2]. Patients and researchers considering Chonluten should therefore regard it as an investigational compound with limited evidence base, used primarily in jurisdictions where short peptides are sold over-the-counter or as dietary supplements.
Clinical Trial Efficacy Highlights
- starKhavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology have published multiple studies in Russian and English describing Chonluten's effects on bronchial epithelial regeneration, antioxidant enzyme upregulation, and stress-response gene modulation (c-Fos, HSP70) in animal models of age-related respiratory decline [1].
- starCell culture studies indicate that EDG tripeptide modulates expression of genes involved in differentiation and proliferation of bronchial epithelial cells, including increases in mucin and surfactant-associated gene expression, supporting a role in mucosal barrier restoration [2].
- starAnimal models of chronic obstructive pulmonary disease report that Chonluten administration reduces inflammatory infiltrate, normalizes alveolar architecture, and improves indices of respiratory mechanics relative to untreated controls, supporting its inclusion in Russian-language respiratory rehabilitation protocols [1].
- starGerontological studies in aged rodents document age-associated declines in bronchial ciliated cell density, mucociliary clearance, and antioxidant enzyme activity that are partially reversed by cyclic Chonluten administration, supporting the bioregulator hypothesis underpinning the Khavinson program [2].
- starKhavinson's broader peptide bioregulator program has been associated with reported increases in median and maximal lifespan in rodent models when peptides are administered cyclically over years; these findings are primarily published by the Khavinson group and have not been independently replicated in large external studies.
- starIndependent biophysical evaluation of the proposed direct DNA-binding mechanism of Khavinson short peptides has been limited and criticized in the broader peptide structural biology literature, although changes in gene expression in cells exposed to short peptides have been observed and require alternative mechanistic explanations.
- starNo randomized controlled clinical trials of Chonluten in human respiratory disease have been published in peer-reviewed English-language journals, and the peptide has not been evaluated by the FDA, EMA, or other major regulatory authorities; clinical use is therefore investigational and unregulated [1].
Side Effects & Tolerability Profile
Clinical subjects transiently report mild side effects. Slowly escalating the titration dose represents the single most effective intervention to limit side effects.
- warningChonluten is reported to be exceptionally well tolerated in Russian-language literature, with rare injection-site reactions and no documented systemic toxicity at standard cyclic doses, although independent safety data are limited.
- warningInjection-site reactions including erythema, mild swelling, and transient itching are the most commonly reported adverse events with subcutaneous administration of any short peptide bioregulator.
- warningHypersensitivity reactions are possible but rarely reported with Khavinson short peptides, possibly because of the very small size and minimal immunogenicity of the tripeptide.
- warningTheoretical risks of broad gene-expression modulation include effects on tissues other than the intended bronchopulmonary target; this concern is mitigated by the limited systemic exposure but is not fully characterized.
- warningLong-term safety of cyclic Chonluten administration beyond a few years has not been evaluated in published prospective studies, and effects on cancer biology in patients with active or treated malignancy are unknown.
- warningSterile injection technique is essential because Chonluten is typically sold as research-grade lyophilized peptide of variable purity, with associated risks of cutaneous infection.
- warningUse during pregnancy, lactation, and in pediatric populations has not been studied and is generally discouraged.
Subcutaneous Injection Technique
Most research peptides require subcutaneous injection into fatty tissue. Never inject directly into a blood vessel or deep muscle tissue unless clinically detailed.
1. Site Selection
Common locations include the abdomen (2 inches from navel), outer upper arms, or thighs.
2. Sanitization
Thoroughly clean the selected site, stopper and vial top using 70% isopropyl alcohol prep swabs.
3. Angle & Push
Pinch the skin and insert the needle at a 45 to 90-degree angle. Depress plunger smoothly.
4. Site Rotation
Rotate injection sites continuously to avoid lipodystrophy or tissue scarring.
Frequently Asked Questions
What is the typical Chonluten dosage?expand_more
Research subcutaneous protocols typically use 100–200 mcg per day for 10–20 day cycles, with cycles repeated every three to six months. Russian-language protocols sometimes use higher cumulative doses in extended courses for chronic respiratory disease. No validated FDA-approved dose exists.
How is Chonluten administered?expand_more
Chonluten is most commonly administered by subcutaneous injection, with intranasal and oral formulations also reported in Russian sources. The lyophilized peptide is reconstituted with bacteriostatic water and injected into the abdomen using an insulin syringe.
Can Chonluten be combined with other compounds?expand_more
Chonluten is often combined with other Khavinson short peptides such as Bronchogen (AEDL) for respiratory, Vesugen (KED) for vascular, and Pinealon (EDR) for neuro support. Stacking with conventional respiratory therapies (inhalers, corticosteroids) has not been formally studied.
What are the side effects of Chonluten?expand_more
Reported tolerability is excellent, with mild injection-site reactions as the most common observation. Hypersensitivity reactions are rare. Long-term safety in humans is uncharacterized, and use in pregnancy, lactation, pediatrics, or active malignancy is generally discouraged.
Is Chonluten FDA approved?expand_more
No. Chonluten is not approved by the FDA, EMA, or any other major regulatory authority. It is registered in Russia and several CIS countries as a dietary supplement or biologically active food additive (BAA), not as a drug. Use elsewhere is investigational.
Academic References & Study Citations
Khavinson VK, Popovich IG, Linkova NS, Mironova ES, Ilina AR. Peptide regulation of gene expression: a systematic review. Molecules. 2021;26(22):7053. View Scientific Paper →
Khavinson VK, Solov'ev AY, Tarnovskaya SI, Lin'kova NS. Mechanism of biological activity of short peptides: cell penetration and epigenetic regulation of gene expression. Biol Bull Rev. 2013;3(6):451-455. View Scientific Paper →
Khavinson VK. Peptides and ageing. Neuroendocrinol Lett. 2002;23 Suppl 3:11-144. View Scientific Paper →
Anisimov VN, Khavinson VK. Peptide bioregulation of aging: results and prospects. Biogerontology. 2010;11(2):139-149. View Scientific Paper →
Khavinson VK, Tarnovskaya SI, Linkova NS, Pronyaeva VE, Shataeva LK, Yakutseni PP. Short cell-penetrating peptides: a model of interactions with gene promoter sites. Bull Exp Biol Med. 2013;154(3):403-410. View Scientific Paper →
Khavinson VK, Linkova NS, Tarnovskaya SI. Short peptides regulate gene expression. Bull Exp Biol Med. 2016;162(2):288-292. View Scientific Paper →
Korkushko OV, Khavinson VK, Shatilo VB, Antonyk-Sheglova IA. Geroprotective effect of epithalamine (pineal gland peptide preparation) in elderly subjects with accelerated aging. Bull Exp Biol Med. 2006;142(3):356-359. View Scientific Paper →
Khavinson VK, Bondarev IE, Butyugov AA. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bull Exp Biol Med. 2003;135(6):590-592. View Scientific Paper →